PIK3CA and head and neck squamous cell carcinoma: A phase Ib clinical trial indicates a novel PI3K inhibitor Alpelisib at 250 mg/d combined with cetuximab and IMRT is tolerable and presents a clinical efficacy in local advanced HNSCC 108.